BioVersys and SARomics Biostructures to Collaborate
News Feb 05, 2014
BioVersys and SARomics Biostructures announced today that they will collaborate and bring
together their complementary expertise to tackle antimicrobial resistance in an international project supported by the European initiative EUROSTARS.
Antimicrobial resistance represents a major threat to public health worldwide and is far from being adequately addressed today, as evidenced by the low number of new products in clinical development. The SARTRIC project addresses this deficiency by restoring antibiotic activity by blocking the transcriptional activation of resistance genes with small molecules and thus restoring the efficacy of already marketed drugs. The two SME (small/medium enterprise) partners BioVersys AG (Basel, Switzerland) and SARomics Biostructures AB (Lund, Sweden) will combine their highly complementary technology modules, expertise and resources to drive the drug development process of initial hit molecules towards fully characterized lead molecules that qualify for preclinical testing. Part of the project will be financed by a Eurostars grant.
“It is a great pleasure to see the synergies between our two companies bearing fruit in an international collaboration with the support and funding of EUROSTARS.” explained Marcel Tigges, CSO at BioVersys.
“We are excited to collaborate with BioVersys on this potentially game-changing
approach that addresses a high unmet medical need.” says Dr. Björn Walse, CEO at
With their ability to treat a wide a variety of diseases, spherical nucleic acids are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A team has developed a direct route to optimize these particles, bringing them one step closer to becoming a viable treatment option for numerous diseases, including cancer.READ MORE